Explore how neoantigen-based vaccines are revolutionizing cancer immunotherapy by enabling personalized, targeted treatment strategies for better outcomes.
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells...